



Prevalence and correlates of oral antibiotic use in Canada

Glenys Smith¹, Anna-Louise Crago^{1*}, Stephanie Alexandre¹, Denise Gravel-Tropper¹, Melissa Isada¹, Braden Knight¹, Jami Mackenzie¹, Jayson Shurgold¹

Abstract

Background: Antimicrobial use (AMU) is a known driver of antimicrobial resistance. Insight into prevalence and correlates of AMU can help identify health inequities and areas for targeted action. To better understand sociodemographic and medical dimensions of AMU in Canada, the Public Health Agency of Canada, in partnership with Statistics Canada, developed a Rapid Response Module questionnaire on self-reported oral antibiotic use, to be administered as part of the 2018 Canadian Community Health Survey (CCHS).

Objective: To provide data on the proportion of people in Canada that self-report the use of antibiotics and sociodemographic and health factors associated with use.

Methods: This cross-sectional study used data from the CCHS, a national survey of 24,176 people with a clustered multi-stage stratified random sampling design. In 2018, an antibiotic use module was administered to CCHS participants.

Results: Among respondents 18 years and older, 26% reported receipt of at least one oral antibiotic over the past year. Several sociodemographic and health factors had higher adjusted odds of receiving an antibiotic prescription, including those aged 18 years compared to aged 48 years (mean), women compared to men, immigrants compared to non-immigrants (excluding Indigenous), current and former smokers compared to those who have never smoked, and those with comorbidities (asthma, chronic obstructive pulmonary disease, arthritis, heart disease, cancer, bowel disorder and urinary incontinence).

Conclusion: Variations in AMU across different key populations and sociodemographic groups highlight the need to improve our understanding of different drivers of AMU and for tailored interventions to reduce inequitable risks of antimicrobial resistance.

Suggested citation: Smith G, Crago A-L, Alexandre S, Gravel Tropper D, Isada M, Knight B, Mackenzie J, Shurgold J. Prevalence and correlates of oral antibiotic use in Canada. *Can Commun Dis Rep* 2024;50(9):312–25. <https://doi.org/10.14745/ccdr.v50i09a04>

Keywords: antibiotic, antibiotic use, antibiotic resistance, antimicrobial resistance, Canadian Community Health Survey, Canada

This work is licensed under a [Creative Commons Attribution 4.0 International License](#).



Affiliation

¹ Antimicrobial Resistance Task Force, Public Health Agency of Canada

*Correspondence:

anna-louise.crago@phac-aspc.gc.ca

Introduction

Antimicrobial resistance (AMR) is an increasing threat to global health (1). In Canada, resistance is increasing for most human pathogens of concern (2). Antibiotic use is associated with the development of antibiotic resistance at the individual, community, and country levels, making it imperative to identify and reduce use that is unnecessary or inappropriate (3,4). While there are no national-level data, studies in Ontario and Alberta have found that 15.4% and 39.2% of antibiotics were

inappropriately prescribed, respectively (5,6). For older adults (over the age of 65 years), evidence from Ontario and British Columbia suggests that 50% of antibiotics in the community are prescribed for conditions not requiring antibiotics (7).

There is robust evidence of sociodemographic differences in antibiotic use in high-income countries, with a dominant trend of higher use among the elderly, people with underlying medical



conditions, women, people with a low income, people with low formal education and various ethnic groups (8). This suggests differential drivers of antibiotic use some of which may be linked to health inequities such as disparities in the burden of infection among different population groups or differential rates of inappropriate prescriptions.

While national surveillance of human antimicrobial use (AMU) in Canada reports on the tonnage of antibiotics and number of antibiotic prescriptions dispensed by Canadian pharmacies (2), this study provides self-reported data on the proportion of people in Canada reporting use of antibiotics and sociodemographic and health factors associated with AMU. These data are key to elucidating drivers of AMU, developing strategies for community-based antibiotic stewardship and preventing AMR health inequities.

Methods

Data source, study design and sample population

This cross-sectional study used data from the Canadian Community Health Survey (CCHS), a voluntary national survey with a clustered multi-stage stratified random sampling design that collects information on health status, determinants of health and healthcare utilization (9). There are certain limitations to the sampling methodology, as it excludes those living on reserves or other Indigenous settlements, institutionalized populations (e.g., residents of healthcare facilities, prisons, convents), full-time members of the Canadian Forces, children living in foster care and residents of the remote Québec regions of Nunavik and Terres-Cries-de-la-Baie-James (9). Altogether, these exclusions represent less than 3% of the Canadian population aged 12 years and over (9).

Along with the core questions of the CCHS, the rapid response component is offered to organizations interested in national estimates on an emerging or specific issue related to the population's health (9). To gain further insights into antibiotic use in humans within Canada, the Public Health Agency of Canada, in partnership with Statistics Canada, developed a Rapid Response Module questionnaire on AMU. Between January 2 and June 30, 2018, a nine-question antimicrobial use Rapid Response Module with a focus on antibiotics was administered to 24,176 consenting CCHS participants from all provinces (the territories were excluded). We excluded participants who responded with "don't know", "not stated", or "refused" when asked if they had received antibiotic prescriptions in the past year ($n=250$), resulting in a final total of 23,926 Canadians aged 18 years and older. Relevant information, including prescribing facility, whether guidance on use was provided, adherence, type of non-adherence, medical reason for prescription and the fate of leftover antibiotics was associated with each outcome. For the

complete list of the AMU Rapid Response Module items, please refer to **Appendix**.

Outcome variable

The outcome for the logistic regression was receipt of one or more outpatient oral antibiotic medication prescription(s) in the 12 months prior to survey administration, regardless of whether the participant filled the prescription.

Exposure variables

Pre-selected sociodemographic exposure variables were chosen based on clinical plausibility and previous literature. They included age, sex, highest household level of education, household income, smoking status, marital status and specific chronic medical conditions captured in the CCHS (9). Body mass index, immigrant/Indigenous status, receipt of previous year influenza vaccination, access to a regular healthcare provider and insurance for prescription medications was also explored. Perceived physical and mental health, as well as perceived stress were also assessed.

Statistical analysis

Descriptive statistics were used to summarize responses from the AMU Rapid Response Module. Adjusted and unadjusted multivariable logistic regression analyses were performed to evaluate the association between previous year AMU and the pre-selected exposure variables. Age was defined using a five-knot restricted cubic spline (10) and all other variables were treated as categorical. Each variable was included in a separate logistic regression model to examine its unadjusted effect on AMU in the previous 12 months. A final model, with all predefined exposure variables, was used to determine which factors maintained their association with AMU in the previous 12 months, adjusting for all other variables. The model included the following variables: sex, age, highest level of education, smoking status, Indigenous status (off-reserve), immigrant status, total household income (in thousands), perceived health, perceived life stress, having asthma, having chronic obstructive pulmonary disease, having arthritis, having high blood pressure, having high blood cholesterol/lipids, having heart disease, ever having been diagnosed with cancer, having a bowel disorder (Crohn's disease, ulcerative colitis, irritable bowel syndrome, incontinence), having urinary incontinence, usual place for immediate care for minor problems, regular provider type, province of residence, marital status, body mass index, type of drinker, level of physical activity, insurance for prescription medications, language most often spoken at home, perceived mental health, having received a seasonal flu shot, having had a stroke, having diabetes, having a mood disorder and having an anxiety disorder. Statistical significance was set at a p -value of ≤ 0.05 .

Given the complex sampling strategy of the CCHS, participants had unequal probabilities of being selected for the survey. To account for this, the logistic regression applied sampling



weights provided by Statistics Canada to extrapolate the results to the overall Canadian population represented by the CCHS. Bootstrapping weights were used to estimate 95% confidence intervals through a bootstrap variance estimation method (1,000 replications).

All analyses were conducted using SAS Enterprise Guide 7.1 (SAS Institute, Cary, North Carolina, United States). To allow for the proper application of the sampling and bootstrap replicate weights, SAS survey analysis procedures were used.

Results

Among the CCHS survey respondents 18 years of age or older who completed the 2018 AMU Rapid Response Module (n=23,926, representing a weighted national population of 29,020,553), 26.0% (95% CI: 24.96%–26.99%) reported receipt of at least one oral antibiotic during the previous year (**Table 1**). Of these, 38.2% (95% CI: 36.16%–40.21%) reported receiving more than one prescription. The majority of patients received their antibiotic prescription from community physician clinics (81.8%, 95% CI: 78.19%–85.36%). The reason for prescription

Table 1: Responses to antimicrobial use questions asked in the Canadian Community Health Survey

Responses	Unweighted		Weighted	
	Frequency	Percent (%)	Frequency	Percent (%)
Did you receive a prescription for antibiotics in the past 12 months (oral antibiotic)?				
Yes	6,407	26.78	7,537,172 (7,243,253–7,831,091)	25.97 (24.96–26.99)
Did not fill prescription ^a	61	0.95	49,548 (33,225–65,872)	0.66 (0.44–0.88)
Still taking it	189	2.95	200,614 (153,032–248,195)	2.66 (2.04–3.29)
No	17,519	73.22	21,483,380 (21,189,461–21,777,300)	74.03 (73.01–75.04)
Did you receive more than one prescription in the past 12 months?				
Yes	2,541	39.66	2,878,101 (2,691,207–3,064,995)	38.19 (36.16–40.21)
No, just one	3,866	60.34	4,659,071 (4,420,023–4,898,120)	61.81 (59.79–63.84)
Why were you given a prescription for antibiotics?				
Chest infection	1,430	21.90	1,617,409 (1,445,932–1,788,885)	21.46 (19.41–23.51)
Ear/nose/throat/sinus/eye infection	1,467	22.90	1,750,049 (1,604,002–1,896,095)	23.22 (21.41–25.02)
Urinary tract infection	978	15.26	1,122,468 (1,002,702–1,242,234)	14.89 (13.39–16.39)
Skin infection	484	7.55	608,859 (502,866–714,851)	8.08 (6.72–9.43)
Gastrointestinal infection	253	3.95	325,678 (259,782–391,573)	4.32 (3.46–5.18)
Other	1,822	28.44	2,112,711 (1,948,239–2,277,183)	28.03 (26.1–29.96)
Where did you receive the prescription?				
Walk-in/doctor's office	4,227	65.97	5,243,770 (4,986,062–5,501,478)	69.57 (67.47–71.67)
Outpatient clinic	991	15.47	919,754 (799,370–1,040,139)	12.2 (10.72–13.69)
Inpatient	272	4.25	263,550 (213,118–313,982)	3.5 (2.83–4.17)
Dentist	745	11.63	877,336 (770,540–984,133)	11.64 (10.27–13.01)
Another place	172	2.68	232,762 (170,137–295,387)	3.09 (2.26–3.92)

^a Weighted frequencies have limited interpretation due to small response rates



was most commonly for infections of the upper respiratory tract (nose, throat or sinus), ear and eye (23.2% combined, 95% CI: 21.41%–25.02%), followed by chest infections (21.5%, 95% CI: 19.41%–23.51%).

The mean age of respondents was 48.1 years old, which served as the reference for the logistic regression models. After

adjusting for all other exposure variables, those aged 18 years had much higher odds, 1.70 (95% CI: 1.29–2.23) compared to those aged 48 years (**Table 2**). Adults aged 30 years had odds of 1.42 (95% CI: 1.23–1.63); at age 60, the odds were 1.01 (95% CI: 0.88–1.16) and at age 80, the odds were 1.11 (95% CI: 0.89–1.37) compared to those aged 48 years (see **Figure 1** for unadjusted odds and **Figure 2** for adjusted odds).

Table 2: Characteristics associated with receiving an antibiotic prescription in the previous 12 months

Characteristics	Unweighted		p-value	Odds ratio	
	Frequency	Percent (%)		Unadjusted	Adjusted
Age (years)					
Mean (SEM)	48.11 (48.0–48.22)		<0.0001	See Figure 1 and Figure 2	
18–29	5,472,681 (5,303,207–5,642,156)	18.86 (18.27–19.44)	-	Not included in model, age was treated as continuous	
30–39	5,255,468 (5,017,771–5,493,165)	18.11 (17.29–18.93)			
40–49	4,668,792 (4,508,772–4,828,812)	16.09 (15.54–16.64)			
50–59	5,013,909 (4,856,837–5,170,981)	17.28 (16.74–17.82)			
60–69	4,698,262 (4,497,236–4,899,288)	16.19 (15.5–16.88)			
70–79	2,693,963 (2,572,919–2,815,007)	9.28 (8.87–9.7)			
80+	1,217,479 (1,125,974–1,308,983)	4.2 (3.88–4.51)			
Sex			<0.0001		
Female	14,742,425 (14,742,424–14,742,426)	50.8 (50.8–50.8)	-	1.65 (1.49–1.83)	1.55 (1.38–1.72)
Male	14,278,128 (14,278,127–14,278,128)	49.2 (49.2–49.2)		Ref.	
Highest level of education			0.0029		
High school	10,333,492 (9,999,596–10,667,387)	35.61 (34.46–36.76)	-	0.91 (0.79–1.05)	0.77 (0.66–0.89)
Diploma	10,371,261 (10,058,907–10,683,616)	35.74 (34.66–36.82)		0.95 (0.84–1.07)	0.88 (0.77–1.01)
University	8,315,800 (7,987,390–8,644,210)	28.65 (27.52–29.79)			Ref.
Smoking status			0.0063		
Current	4,872,020 (4,617,655–5,126,385)	16.79 (15.91–17.67)	-	1.31 (1.13–1.51)	1.3 (1.11–1.53)
Experiment	3,914,117 (3,696,472–4,131,761)	13.49 (12.74–14.24)		1.11 (0.94–1.29)	1.14 (0.97–1.34)
Former	7,704,652 (7,421,722–7,987,581)	26.55 (25.57–27.53)		1.2 (1.06–1.36)	1.22 (1.06–1.4)
Never	12,529,764 (12,185,432–12,874,096)	43.18 (41.99–44.36)		Ref.	
Indigenous (off-reserve)/immigrant status			0.1067		
Indigenous (off-reserve)	978,508 (870,556–1,086,460)	3.37 (3.0–3.74)	-	1.2 (0.94–1.53)	1.04 (0.81–1.34)
Immigrant	7,492,618 (7,126,684–7,858,551)	25.82 (24.56–27.08)	-	0.94 (0.82–1.08)	1.21 (1.01–1.45)
Non-Indigenous/non-immigrant	20,549,427 (20,193,939–20,904,9150)	70.81 (69.58–72.04)	-	Ref.	



Table 2: Characteristics associated with receiving an antibiotic prescription in the previous 12 months (continued)

Characteristics	Unweighted		p-value	Odds ratio	
	Frequency	Percent (%)		Unadjusted	Adjusted
Total household income (thousands)				0.7555	
<50	7,588,111 (7,288,500–7,887,721)	26.15 (25.11–27.18)	-	1.11 (0.93–1.31)	0.94 (0.78–1.14)
50–100	9,303,183 (9,011,645–9,594,722)	32.06 (31.05–33.06)		0.99 (0.84–1.16)	0.92 (0.78–1.09)
100–149	6,033,084 (5,772,751–6,293,418)	20.79 (19.89–21.69)		0.97 (0.82–1.15)	0.92 (0.77–1.09)
>150	6,096,174 (5,804,118–6,388,231)	21.01 (20.00–22.01)		Ref.	
Perceived health				<0.0001	
Poor/fair	3,487,551 (3,276,377–3,698,725)	12.02 (11.29–12.75)	-	2.82 (2.36–3.38)	1.89 (1.45–2.46)
Good	8,341,719 (8,033,243–8,650,196)	28.74 (27.68–29.81)		1.75 (1.51–2.04)	1.47 (1.22–1.75)
Very good	10,588,084 (10,279,864–10,896,303)	36.48 (35.42–37.55)		1.47 (1.27–1.7)	1.34 (1.14–1.57)
Excellent	6,603,198 (6,323,648–6,882,749)	22.75 (21.79–23.72)		Ref.	
Perceived life stress				0.0003	
Not at all stressful	3,957,912 (3,760,455–4,155,369)	13.64 (12.96–14.32)	-	Ref.	
Not very stressful	6,783,011 (6,515,591–7,050,432)	23.37 (22.45–24.3)		1.35 (1.13–1.61)	1.29 (1.07–1.55)
A bit stressful	11,999,017 (11,679,691–12,318,343)	41.35 (40.24–42.45)		1.61 (1.36–1.91)	1.42 (1.18–1.72)
Stressful	6,280,612 (5,995,955–6,565,269)	21.64 (20.66–22.62)		2.05 (1.68–2.51)	1.62 (1.29–2.04)
Chronic medical condition(s)					
Has asthma	2,413,833 (2,237,478–2,590,188)	8.32 (7.71–8.93)	0.0001	1.88 (1.58–2.24)	1.44 (1.2–1.74)
Has chronic obstructive pulmonary disease	838,936 (743,407–934,466)	2.89 (2.56–3.22)	<0.0001	2.83 (2.23–3.59)	1.92 (1.45–2.53)
Has arthritis	5,790,867 (5,564,474–6,017,260)	19.95 (19.17–20.74)	0.0001	1.57 (1.4–1.75)	1.29 (1.13–1.47)
Has high blood pressure	5,326,295 (5,092,116–5,560,473)	18.35 (17.55–19.16)	0.0249	1.08 (0.96–1.21)	0.85 (0.74–0.98)
Has high blood cholesterol/lipids	3,686,570 (3,491,111–5,560,473)	12.7 (12.03–13.38)	0.4780	1.21 (1.06–1.39)	1.06 (0.9–1.25)
Has heart disease	1,382,509 (1,248,851–1,516,167)	4.76 (4.3–5.23)	0.0004	1.72 (1.43–2.07)	1.45 (1.18–1.79)
Ever been diagnosed with cancer	2,175,846 (2,030,344–2,321,349)	7.5 (7.0–8.0)	0.0157	1.41 (1.22–1.62)	1.23 (1.04–1.46)
Has a bowel disorder (Crohn's disease, ulcerative colitis, irritable bowel syndrome, incontinence)	1,558,896 (1,431,507–1,686,285)	5.37 (4.93–5.81)	0.0080	1.91 (1.63–2.24)	1.27 (1.07–1.52)
Has urinary incontinence	1,146,488 (1,028,631–1,265,228)	3.95 (3.54–4.36)	0.0265	1.85 (1.5–2.27)	1.31 (1.03–1.67)
Usual place for immediate care for minor problems				<0.0001	
Community health centre	1,146,488 (1,030,584–1,262,392)	3.95 (3.55–4.35)	-	0.77 (0.6–0.98)	0.78 (0.6–1.02)
Doctor's office	14,534,280 (14,210,494–14,858,067)	50.08 (48.97–51.2)		Ref.	



Table 2: Characteristics associated with receiving an antibiotic prescription in the previous 12 months (continued)

Characteristics	Unweighted		p-value	Odds ratio	
	Frequency	Percent (%)		Unadjusted	Adjusted
Usual place for immediate care for minor problems (continued)				<0.0001	
Emergency room	1,944,944 (1,792,576–2,097,311)	6.7 (6.18–7.23)	-	0.91 (0.74–1.11)	1 (0.8–1.23)
Hospital outpatient	725,183 (642,555–807,811)	2.5 (2.21–2.78)		0.82 (0.64–1.06)	0.83 (0.63–1.08)
Walk-in clinic	6,889,707 (6,603,742–7,175,672)	23.74 (22.75–24.73)		0.99 (0.87–1.13)	1.1 (0.95–1.26)
No usual place of care	3,779,951 (3,566,350–3,993,551)	13.03 (12.29–13.76)		0.56 (0.46–0.66)	0.66 (0.54–0.8)
Regular provider type				0.0004	
FP/GP	23,941,588 (23,683,672–24,199,503)	82.5 (81.61–83.39)	-	Ref.	
Non-FP/GP	732,110 (605,057–859,163)	2.52 (2.08–2.96)		0.87 (0.62–1.23)	0.84 (0.58–1.23)
No usual provider	4,346,855 (4,123,637–4,570,073)	14.98 (14.21–15.75)		0.61 (0.53–0.71)	0.71 (0.6–0.84)

Abbreviations: FP, family practitioner; GP, general practitioner; Ref., reference; SEM, standard error of the mean
Note: These additional covariates were also included in the model: province of residence, marital status, body mass index, type of drinker, physical activity, insurance for prescription medications, language most often spoken at home, perceived mental health, seasonal flu shot, stroke, diabetes, mood disorder and anxiety disorder. Adjusted and unadjusted results for these covariates can be found in the Appendix

Figure 1: Unadjusted odds ratio for oral antibiotic use in the past 12 months by age





Figure 2: Adjusted odds ratio for oral antibiotic use in the past 12 months by age



In the adjusted model, women had higher odds of reporting receipt of an antibiotic prescription in the previous 12 months compared to men (OR 1.55; 95% CI: 1.38–1.72) (Table 2). Using the adjusted logistic regression model, immigrants were 1.21 (95% CI: 1.01–1.45) times more likely than those who were both non-Indigenous and non-immigrants to report receiving an antibiotic prescription. For Indigenous respondents (off-reserve), the odds were 1.04 (95% CI: 0.81–1.34) times higher, however, it was not possible to determine if this difference was significant due to the small number of Indigenous respondents (3.37%).

Respondents who reported having no usual place of care for minor medical problems (OR 0.66; 95% CI: 0.54–0.80) or no regular healthcare provider (OR 0.71; 95% CI: 0.60–0.84) were less likely to receive an antibiotic prescription after adjusting for all other covariates (Table 2).

Those who self-reported less than excellent health and perceived life stress had greater odds of receiving an antibiotic prescription. Both current and former smokers had higher odds compared to those who had never smoked. Asthma, chronic obstructive pulmonary disease, arthritis, heart disease, cancer, bowel disorders and urinary incontinence were associated with an increased odds of receiving a prescription. Hypertension was associated with lower odds. The frequency of responses was too low to include receipt of seasonal influenza vaccination in the model.



Discussion

This study revealed that about one-quarter of Canadians (26.0%) received at least one systemic (oral) antibiotic prescription over a one-year period, of whom 38% received more than one. One in five of these prescriptions (21.5%) was reported to be for a chest infection. This is concerning given that bronchitis has been found to be associated with high levels of unnecessary antibiotic prescribing in other research (52% in British Columbia (11); 53% in Ontario) (5). The high proportion of reported prescriptions for ear/nose/throat/sinus/eye infections (23.2%) is similarly notable, given that previous research has found a high rate of unnecessary prescribing for sinus infections (48% in British Columbia; 48% in Ontario), throat infections (42% in British Columbia) and ear infections (39% in Ontario) (5,11).

After controlling for medical conditions, the odds of those aged 18 years and those aged 30 years having received a prescription were higher than those aged 48 years, 60 years and 80 years. It is expected for antibiotic use to rise with age and for much of it to be attributable to greater morbidity, however, it is unclear what underpins young adults' odds of use such that it surpasses the odds for middle-age and older adults when controlling for medical conditions. Younger adults may be more likely to have a faulty understanding of what constitutes an oral antibiotic. As well, this survey does not capture the frailest older adults, such as long-term care residents or those in hospital, possibly eliminating a large portion of antibiotic use in these disproportionately elderly groups. Population usage metrics show a greater burden of antibiotic use among older age groups (2). Taken together, these different measures might also indicate that those older adults who use antibiotics use a high quantity (by tonnage or by prescription) while young adults may have more evenly distributed use across their age groups or shorter prescriptions. These findings are similar to those of other surveys on antibiotic use in Canada that found high reported use among young adults (12,13). Younger age groups also have a much higher burden of conditions that are frequently treated with antibiotics that were not controlled for in our study, such as sexually transmitted infections (14) and acne (15). The widespread and intensive use of systemic antibiotics for acne, particularly among young adults, has notably been challenged in recent scientific literature and guidelines have been changed in many regions to reduce their use to limit AMR (16–19). Young adults may also be parents and are more likely to be exposed to respiratory infections through their children (20,21). In some contexts, young adults have a higher rate of inappropriate prescriptions for upper respiratory tract infections than other adult age groups (22,23).

In line with previously published findings in the literature and Canadian dispensation data (2,8), antibiotic use is higher among women. This may be for reasons linked to biology (e.g., a higher risk of urinary tract infections) or gendered social dynamics (e.g., a higher likelihood to seek medical care (24)

and very high representation in work with exposure to patients, children or food-labour sectors associated with higher rates of infections (25)).

Contrary to other studies from high-income countries, neither income nor education were significant in either adjusted or unadjusted analyses (8). This may be because we were able to control for other variables that are often co-linear with socioeconomic status such as comorbidities (positively associated with use) and low levels of access to regular medical care (negatively associated with use).

We found very slightly higher use among Indigenous populations off-reserve. This contrasts with other studies that have found high dispensation rates of antibiotics to Indigenous populations on-reserve and in the Arctic (26,27). However, it is in line with studies that have found that antibiotic use is not highly different in regions with higher Indigenous populations, though the latter studies also appear to have excluded on-reserve dispensations, potentially skewing regional use and its associations (28,29).

The finding of higher use among immigrant populations in Canada departs from a study that found that regions in Ontario with a higher proportion of immigrants had neither higher nor lower use (28).

In accordance with many other findings, several medical conditions were associated with higher antibiotic use, which is potentially explained by the need for invasive devices with elevated risk of infection, depressed immunity, symptoms of unclear etiology or frequent interactions with medical care. The finding that hypertension was associated with lower odds of prescriptions may be explained by known contraindications of blood pressure medications with use of certain antibiotics (30,31).

Limitations

The results are based on self-reported survey data, and responses may reflect recall bias or social desirability bias. Respondents may also have a faulty understanding of what an antibiotic is. This is a common and well-known limitation in surveys of antibiotic use (32–35). While restricting participation to respondents who demonstrate knowledge of antibiotic use could mitigate this issue, it would introduce selection bias (32).

These results do not include the Territories or residents of the remote Québec regions of Nunavik and Terres-Cries-de-la-Baie-James, Indigenous communities, institutionalized populations (e.g., residents of healthcare facilities, long-term care, prisons, convents) and full-time members of the Canadian Armed Forces. This survey does not include unprescribed antibiotic use, which in other contexts has been found to be higher among certain demographics, including migrant workers, men who have sex with men and people who inject drugs (22,36). Additionally, telephone surveys may not capture the frailest community-



dwelling adults and will not capture people without a phone, which may both be key populations for high antibiotic use (8). As well, recent research has highlighted very elevated levels of antibiotic prescribing to gay, bisexual, and other men who have sex with men in an urban sexual health clinic (37), to people living in Arctic communities (27) and to First Nations individuals accessing health care at nursing stations on-reserve in Canada (26). Further research should further inquire into levels of AMU among these populations at a national level.

Conclusion

These results suggest that efforts to reduce unnecessary antibiotic use through stewardship and policy initiatives need to target the whole age spectrum. More data are necessary to understand and address the drivers of antibiotic use and to elucidate why young people have higher odds of being prescribed an antibiotic than those in middle-age when controlling for other factors, similar to what has been seen in other studies (12,13). Medical record data may help elucidate why certain comorbidities are associated with higher antibiotic use and help capture if it is appropriate or not to better tailor stewardship interventions.

In order to best tailor interventions on antibiotic use for immigrant communities, further research is necessary to identify which ethnocultural and linguistic groups are most affected. As well, more research and better data are needed on key populations not included in this study of AMU, including Indigenous people on-reserve and in the Arctic, individuals in long-term care establishments, two-spirit, gay, and bisexual men who have sex with men, transgender populations, incarcerated populations and people who use drugs, particularly by injection.

Notably, just over a quarter of respondents reported having taken systemic oral antibiotics, most frequently for indications for which close to half of prescriptions are known to be inappropriate. This points to the need for better education of prescribers and Canadians on the role of judicious AMU in protecting individual health and the health of the community.

Authors' statement

GS — Writing—original draft, formal analysis, writing—review & editing

A-LC — Writing—original draft, formal analysis, writing—review & editing

SA — Writing—review & editing, formal analysis, supervision, project administration

DG-T — Conceptualization, supervision

MI — Writing—review & editing

BK — Formal analysis, writing—review & editing

JM — Writing—original draft

JS — Formal analysis, writing—review & editing

Competing interests

None.

Acknowledgements

The authors wish to acknowledge Jacqueline Arthur, Stephen Cole, Edward Gertier and Cheryl Marinsky for their contributions to the early stages of this project. The authors also wish to acknowledge the Canadian Community Health Survey team at Statistics Canada.

Funding

This work was supported by the Public Health Agency of Canada.

References

1. Murray CJ, Ikuta KS, Sharara F; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022;399(10325):629–55. [DOI PubMed](#)
2. Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System (CARSS). Report 2022. Ottawa, ON: PHAC; 2022. [DOI](#)
3. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ* 2010;340:c2096–2096. [DOI PubMed](#)
4. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infect Dis* 2014;14(1):13. [DOI PubMed](#)
5. Schwartz KL, Langford BJ, Daneman N, Chen B, Brown KA, McIsaac W, Tu K, Candido E, Johnstone J, Leung V, Hwee J, Silverman M, Wu JH, Garber G. Unnecessary antibiotic prescribing in a Canadian primary care setting: a descriptive analysis using routinely collected electronic medical record data. *CMAJ Open* 2020;8(2):E360–9. [DOI PubMed](#)
6. Leslie M, Fadaak R, Lethebe BC, Szostakiwskyj JH. Assessing the appropriateness of community-based antibiotic prescribing in Alberta, Canada, 2017–2020, using ICD-9-CM codes: a cross-sectional study. *CMAJ Open* 2023;11(4):E579–86. [DOI PubMed](#)
7. Saatchi A, Reid JN, Povitz M, Shariff SZ, Silverman M, Morris AM, Reyes RC, Patrick DM, Marra F. Appropriateness of outpatient antibiotic use in seniors across two Canadian provinces. *Antibiotics (Basel)* 2021;10(12):1484. [DOI PubMed](#)



8. Schmiede D, Evers M, Kistemann T, Falkenberg T. What drives antibiotic use in the community? A systematic review of determinants in the human outpatient sector. *Int J Hyg Environ Health* 2020;226:113497. DOI PubMed
9. Statistics Canada. Canadian Community Health Survey (CCHS). Ottawa, ON: StatCan; 2023. <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=1496481>
10. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Springer Series in Statistics. Springer International Publishing; 2015. https://warin.ca/ressources/books/2015_Book_RegressionModelingStrategies.pdf
11. Saatchi A, Yoo JW, Schwartz KL, Silverman M, Morris AM, Patrick DM, McCormack J, Marra F. Quantifying the gap between expected and actual rates of antibiotic prescribing in British Columbia, Canada. *Antibiotics (Basel)* 2021;10(11):1428. DOI PubMed
12. Crago AL, Alexandre S, Abdesselam K, Tropper DG, Hartmann M, Smith G, Lary T. Understanding Canadians' knowledge, attitudes and practices related to antimicrobial resistance and antibiotic use: results from public opinion research. *Can Commun Dis Rep* 2022;48(11/12):550–8. DOI PubMed
13. Lorcy A, Quakki M, Dubé É. Étude Sur Les Connaissances, Attitudes et Perceptions de La Population Québécoise Sur L'utilisation Des Antibiotiques : 2019. 2020. [Accessed 2023 Dec 5]. <https://www.inspq.qc.ca/publications/2690>
14. Public Health Agency of Canada. Notifiable Disease Charts. Ottawa, ON: PHAC; 2024. <https://diseases.canada.ca/notifiable/charts-list>
15. Bhate K, Williams HC. Epidemiology of acne vulgaris. *Br J Dermatol* 2013;168(3):474–85. DOI PubMed
16. Sinnott SJ, Bhate K, Margolis DJ, Langan SM. Antibiotics and acne: an emerging iceberg of antibiotic resistance? *Br J Dermatol* 2016;175(6):1127–8. DOI PubMed
17. Walsh TR, Efthimiou J, Dréno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. *Lancet Infect Dis* 2016;16(3):e23–33. DOI PubMed
18. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol* 2016;74(5):945–73.e33. DOI PubMed
19. Nast A, Dréno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, Finlay AY, Haedersdal M, Lambert J, Layton A, Lomholt HB, López-Estebarez JL, Ochsendorf F, Oprica C, Rosumeck S, Simonart T, Werner RN, Gollnick H. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. *J Eur Acad Dermatol Venereol* 2016;30(8):1261–8. DOI PubMed
20. Byington CL, Ampofo K, Stockmann C, Adler FR, Herbener A, Miller T, Sheng X, Blaschke AJ, Crisp R, Pavia AT. Community surveillance of respiratory viruses among families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE) Study. *Clin Infect Dis* 2015;61(8):1217–24. DOI PubMed
21. Seibold MA, Moore CM, Everman JL, Williams BJ, Nolin JD, Fairbanks-Mahnke A, Plender EG, Patel BB, Arbes SJ, Bacharier LB, Bendixsen CG, Calatroni A, Camargo CA Jr, Dupont WD, Furuta GT, Gebretsadik T, Gruchalla RS, Gupta RS, Khurana Hershey GK, Murrison LB, Jackson DJ, Johnson CC, Kattan M, Liu AH, Lussier SJ, O'Connor GT, Rivera-Spoljaric K, Phipatanakul W, Rothenberg ME, Seroogy CM, Teach SJ, Zoratti EM, Togias A, Fulkerson PC, Hartert TV; HEROS study team. Risk factors for SARS-CoV-2 infection and transmission in households with children with asthma and allergy: A prospective surveillance study. *J Allergy Clin Immunol* 2022;150(2):302–11. DOI PubMed
22. Grigoryan L, Zoorob R, Shah J, Wang H, Arya M, Trautner BW. Antibiotic prescribing for uncomplicated acute bronchitis is highest in younger adults. *Antibiotics (Basel)* 2017;6(4):22. DOI PubMed
23. Malo S, Bjerrum L, Feja C, Lallana MJ, Moliner J, Rabanaque MJ. Compliance with recommendations on outpatient antibiotic prescribing for respiratory tract infections: the case of Spain. *Basic Clin Pharmacol Toxicol* 2015;116(4):337–42. DOI PubMed
24. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. *BMC Fam Pract* 2016;17(1):38. DOI PubMed



25. Morales-Suárez-Varela M, Kaerlev L, Zhu JL, Llopis-González A, Gimeno-Clemente N, Nohr EA, Bonde JP, Olsen J. Risk of infection and adverse outcomes among pregnant working women in selected occupational groups: A study in the Danish National Birth Cohort. *Environ Health* 2010;9(1):70. [DOI PubMed](#)
26. Jeong D, Nguyen HN, Tyndall M, Schreiber YS. Antibiotic use among twelve Canadian First Nations communities: a retrospective chart review of skin and soft tissue infections. *BMC Infect Dis* 2020;20(1):118. [DOI PubMed](#)
27. Williams K, Colquhoun A, Munday R, Goodman KJ; CANHelp Working Group. Antibiotic dispensation rates among participants in community-driven health research projects in Arctic Canada. *BMC Public Health* 2019;19(1):949. [DOI PubMed](#)
28. Schwartz KL, Achonu C, Brown KA, Langford B, Daneman N, Johnstone J, Garber G. Regional variability in outpatient antibiotic use in Ontario, Canada: a retrospective cross-sectional study. *CMAJ Open* 2018;6(4):E445–52. [DOI PubMed](#)
29. Marra F, Mak S, Chong M, Patrick DM. The relationship among antibiotic consumption, socioeconomic factors and climatic conditions. *Can J Infect Dis Med Microbiol* 2010;21(3):e99–106. [DOI PubMed](#)
30. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. *CMAJ* 2011;183(3):303–7. [DOI PubMed](#)
31. Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. *JAMA* 2013;310(23):2544–53. [DOI PubMed](#)
32. Kosiyaoporn H, Chanvatik S, Issaramalai T, Kaewkhankhaeng W, Kulthanmanusorn A, Saengruang N, Witthayapipopsakul W, Viriyathorn S, Kirivan S, Kunpeuk W, Suphanchaimat R, Lekagul A, Tangcharoensathien V. Surveys of knowledge and awareness of antibiotic use and antimicrobial resistance in general population: A systematic review. *PLoS One* 2020;15(1):e0227973. [DOI PubMed](#)
33. Vanden Eng J, Marcus R, Hadler JL, Imhoff B, Vugia DJ, Cieslak PR, Zell E, Deneen V, McCombs KG, Zansky SM, Hawkins MA, Besser RE. Consumer attitudes and use of antibiotics. *Emerg Infect Dis* 2003;9(9):1128–35. [DOI PubMed](#)
34. Parimi N, Pinto Pereira LM, Prabhakar P. The general public's perceptions and use of antimicrobials in Trinidad and Tobago. *Rev Panam Salud Publica* 2002;12(1):11–8. [DOI PubMed](#)
35. Barah F, Gonçalves V. Antibiotic use and knowledge in the community in Kalamoon, Syrian Arab Republic: a cross-sectional study. *East Mediterr Health J* 2010;16(5):516–21. [DOI PubMed](#)
36. O'Halloran C, Croxford S, Mohammed H, Gill ON, Hughes G, Fifer H, Allen H, Owen G, Nutland W, Delpech V, Saunders JM. Factors associated with reporting antibiotic use as STI prophylaxis among HIV PrEP users: findings from a cross-sectional online community survey, May-July 2019, UK. *Sex Transm Infect* 2021;97(6):429–33. [DOI PubMed](#)
37. Vanbaelen T, Tsoumanis A, Kenyon C. Total Antimicrobial Consumption in Doxycycline Postexposure Prophylaxis Cohorts and the Intensity of Screening for Bacterial Sexually Transmitted Infections. *Clin Infect Dis* 2024;78(3):803–5. [DOI PubMed](#)



Appendix

Table A1: Characteristics associated with receiving an antibiotic prescription in the previous 12 months with all variables

Characteristics	Weighted		Odds ratio	
	Frequency	Percent (%)	Unadjusted	Adjusted
Age (years)				
Mean (SEM)	48.11 (48.0–48.22)		See Figure 1	
18–29	5,472,681 (5,303,207–5,642,156)	18.86 (18.27–19.44)	Not included in model, age was treated as continuous	
30–39	5,255,468 (5,017,771–5,493,165)	18.11 (17.29–18.93)		
40–49	4,668,792 (4,508,772–4,828,812)	16.09 (15.54–16.64)		
50–59	5,013,909 (4,856,837–5,170,981)	17.28 (16.74–17.82)		
60–69	4,698,262 (4,497,236–4,899,288)	16.19 (15.5–16.88)		
70–79	2,693,963 (2,572,919–2,815,007)	9.28 (8.87–9.7)		
80+	1,217,479 (1,125,974–1,308,983)	4.2 (3.88–4.51)		
Sex				
Female	14,742,425 (14,742,424–14,742,426)	50.8 (50.8–50.8)	1.65 (1.49–1.83)	1.55 (1.38–1.72)
Male	14,278,128 (14,278,127–14,278,128)	49.2 (49.2–49.2)	Ref.	
Marital status				
Married/common-law	18,199,194 (17,888,721–18,509,667)	62.71 (61.64–63.78)	Ref.	
Single	7,070,640 (6,828,042–7,313,238)	24.36 (23.53–25.2)	1.03 (0.89–1.18)	0.95 (0.8–1.14)
Widowed/separated/divorced	3,750,719 (3,567,739–3,933,700)	12.92 (12.29–13.56)	1.11 (0.97–1.26)	0.94 (0.8–1.09)
Highest level of education				
High school	10,333,492 (9,999,596–10,667,387)	35.61 (34.46–36.76)	0.91 (0.79–1.05)	0.77 (0.66–0.89)
Diploma	10,371,261 (10,058,907–10,683,616)	35.74 (34.66–36.82)	0.95 (0.84–1.07)	0.88 (0.77–1.01)
University	8,315,800 (7,987,390–8,644,210)	28.65 (27.52–29.79)	Ref.	
Body mass index				
Underweight	420,444 (330,287–510,601)	1.45 (1.14–1.76)	0.98 (0.6–1.61)	0.79 (0.46–1.33)
Normal weight	9,389,187 (9,068,169–9,710,205)	32.35 (31.25–33.46)	Ref.	
Overweight	10,036,834 (9,720,884–10,352,785)	34.59 (33.5–35.68)	0.91 (0.8–1.03)	0.97 (0.84–1.11)
Obese I	4,724,310 (4,496,430–4,952,190)	16.28 (15.49–17.07)	1.07 (0.92–1.23)	1.03 (0.88–1.21)
Obese II	1,645,989 (1,503,982–1,787,997)	5.67 (5.18–6.16)	1.38 (1.13–1.69)	1.24 (1.0–1.54)
Obese III	897,816 (788,814–1,006,819)	3.09 (2.72–3.47)	1.49 (1.14–1.95)	1.18 (0.89–1.56)
Unknown	1,905,972 (1,730,180–2,081,763)	6.57 (5.96–7.17)	0.99 (0.79–1.23)	0.84 (0.66–1.07)

**Table A1: Characteristics associated with receiving an antibiotic prescription in the previous 12 months with all variables (continued)**

Characteristics	Weighted		Odds ratio	
	Frequency	Percent (%)	Unadjusted	Adjusted
Smoking status				
Current	4,872,020 (4,617,655–5,126,385)	16.79 (15.91–17.67)	1.31 (1.13–1.51)	1.3 (1.11–1.53)
Experiment	3,914,117 (3,696,472–4,131,761)	13.49 (12.74–14.24)	1.11 (0.94–1.29)	1.14 (0.97–1.34)
Former	7,704,652 (7,421,722–7,987,581)	26.55 (25.57–27.53)	1.2 (1.06–1.36)	1.22 (1.06–1.4)
Never	12,529,764 (12,185,432–12,874,096)	43.18 (41.99–44.36)		Ref.
Type of drinker (last 12 months)				
Never	6,098,171 (5,786,026–6,410,317)	21.01 (19.94–22.09)		Ref.
Occasional	4,861,665 (4,609,049–5,114,282)	16.75 (15.88–17.62)	1.04 (0.88–1.22)	1.0 (0.84–1.19)
Regular	18,060,716 (17,708,394–18,413,038)	62.23 (61.02–63.45)	0.93 (0.81–1.06)	1.0 (0.86–1.15)
Physical activity				
Active	10,675,829 (10,346,693–11,004,965)	36.79 (35.65–37.92)		Ref.
Moderately active	4,926,604 (4,685,618–5,167,590)	16.98 (16.14–17.81)	1.15 (0.99–1.34)	1.08 (0.93–1.26)
Somewhat active	6,472,529 (6,191,847–6,753,211)	22.3 (21.33–23.27)	1.14 (1.0–1.31)	1.05 (0.91–1.21)
Sedentary	6,945,590 (6,672,435–7,218,745)	23.93 (22.99–24.88)	1.14 (1.0–1.3)	1.0 (0.86–1.16)
Indigenous (off-reserve)/immigrant status				
Indigenous (off-reserve)	978,508 (870,556–1,086,460)	3.37 (3.0–3.74)	1.2 (0.94–1.53)	1.04 (0.81–1.34)
Immigrant	7,492,618 (7,126,684–7,858,551)	25.82 (24.56–27.08)	0.94 (0.82–1.08)	1.21 (1.01–1.45)
Non-Indigenous/non-immigrant	20,549,427 (20,193,939–20,904,915)	70.81 (69.58–72.04)		Ref.
Language most often spoken at home (first answer)				
English	18,759,089 (18,414,234–19,103,944)	64.64 (63.45–65.83)		Ref.
French	5,915,950 (5,767,569–6,064,331)	20.39 (19.87–20.9)	0.97 (0.87–1.08)	1.05 (0.82–1.35)
Other	4,345,514 (3,998,878–4,692,150)	14.97 (13.78–16.17)	0.82 (0.69–0.98)	0.89 (0.7–1.12)
Total household income (thousands)				
<50	7,588,111 (7,288,500–7,887,721)	26.15 (25.11–27.18)	1.11 (0.93–1.31)	0.94 (0.78–1.14)
50–100	9,303,183 (9,011,645–9,594,722)	32.06 (31.05–33.06)	0.99 (0.84–1.16)	0.92 (0.78–1.09)
100–149	6,033,084 (5,772,751–6,293,418)	20.79 (19.89–21.69)	0.97 (0.82–1.15)	0.92 (0.77–1.09)
>150	6,096,174 (5,804,118–6,388,231)	21.01 (20.0–22.01)		Ref.
Province of residence				
Alberta	3,319,229 (3,319,228–3,319,229)	11.44 (11.44–11.44)	1.02 (0.87–1.2)	1.05 (0.89–1.24)



Table A1: Characteristics associated with receiving an antibiotic prescription in the previous 12 months with all variables (continued)

Characteristics	Weighted		Odds ratio	
	Frequency	Percent (%)	Unadjusted	Adjusted
Province of residence (continued)				
British Columbia	3,867,378 (3,867,377–3,867,378)	13.33 (13.33–13.33)	1.02 (0.87–1.19)	1.07 (0.9–1.27)
Manitoba	977,254 (977,254–977,254)	3.37 (3.37–3.37)	0.99 (0.8–1.22)	1.11 (0.88–1.39)
New Brunswick	603,559 (603,559–603,560)	2.08 (2.08–2.08)	1.1 (0.87–1.38)	1.12 (0.87–1.44)
Newfoundland and Labrador	428,946 (428,946–428,947)	1.48 (1.48–1.48)	1.27 (1.0–1.6)	1.42 (1.1–1.84)
Nova Scotia	768,501 (768,501–768,501)	2.65 (2.65–2.65)	1.19 (0.98–1.44)	1.17 (0.94–1.45)
Ontario	11,377,324 (11,377,324–11,377,324)	39.2 (39.2–39.2)	Ref.	
Prince Edward Island	120,209 (120,209–120,209)	0.41 (0.41–0.41)	1.29 (1.0–1.67)	1.39 (1.04–1.86)
Québec	6,712,348 (6,712,347–6,712,348)	23.13 (23.13–23.13)	0.99 (0.87–1.13)	1.1 (0.86–1.42)
Saskatchewan	845,805 (845,805–845,805)	2.91 (2.91–2.91)	1.07 (0.87–1.33)	1.12 (0.89–1.41)
Perceived health				
Poor/fair	3,487,551 (3,276,377–3,698,725)	12.02 (11.29–12.75)	2.82 (2.36–3.38)	1.89 (1.45–2.46)
Good	8,341,719 (8,033,243–8,650,196)	28.74 (27.68–29.81)	1.75 (1.51–2.04)	1.47 (1.22–1.75)
Very good	10,588,084 (10,279,864–10,896,303)	36.48 (35.42–37.55)	1.47 (1.27–1.7)	1.34 (1.14–1.57)
Excellent	6,603,198 (6,323,648–6,882,749)	22.75 (21.79–23.72)	Ref.	
Perceived mental health				
Poor/fair	2,103,157 (1,926,551–2,279,763)	7.25 (6.64–7.86)	2.01 (1.64–2.48)	1.03 (0.79–1.33)
Good	7,680,865 (7,390,689–7,971,041)	26.47 (25.47–27.47)	1.45 (1.26–1.67)	1.07 (0.91–1.26)
Very good	10,430,576 (10,111,131–10,750,020)	35.94 (34.84–37.04)	1.08 (0.95–1.22)	0.9 (0.78–1.03)
Excellent	8,805,955 (8,505,460–9,106,450)	30.34 (29.31–31.38)	Ref.	
Perceived life stress				
Not at all stressful	3,957,912 (3,760,455–4,155,369)	13.64 (12.96–14.32)	Ref.	
Not very stressful	6,783,011 (6,515,591–7,050,432)	23.37 (22.45–24.3)	1.35 (1.13–1.61)	1.29 (1.07–1.55)
A bit stressful	11,999,017 (11,679,691–12,318,343)	41.35 (40.24–42.45)	1.61 (1.36–1.91)	1.42 (1.18–1.72)
Stressful	6,280,612 (5,995,955–6,565,269)	21.64 (20.66–22.62)	2.05 (1.68–2.51)	1.62 (1.29–2.04)
Had a seasonal flu shot (current/last year)	56,010 (36,132–75,888)	0.19 (0.12–0.26)	Frequency too low to include in model	
Chronic medical condition(s)				
Has asthma	2,413,833 (2,237,478–2,590,188)	8.32 (7.71–8.93)	1.88 (1.58–2.24)	1.44 (1.2–1.74)

**Table A1: Characteristics associated with receiving an antibiotic prescription in the previous 12 months with all variables (continued)**

Characteristics	Weighted		Odds ratio	
	Frequency	Percent (%)	Unadjusted	Adjusted
Chronic medical condition(s) (continued)				
Has chronic obstructive pulmonary disease	838,936 (743,407–934,466)	2.89 (2.56–3.22)	2.83 (2.23–3.59)	1.92 (1.45–2.53)
Has arthritis	5,790,867 (5,564,474–6,017,260)	19.95 (19.17–20.74)	1.57 (1.4–1.75)	1.29 (1.13–1.47)
Has high blood pressure	5,326,295 (5,092,116–5,560,473)	18.35 (17.55–19.16)	1.08 (0.96–1.21)	0.85 (0.74–0.98)
Has high blood cholesterol/lipids	3,686,570 (3,491,111–3,882,029)	12.7 (12.03–13.38)	1.21 (1.06–1.39)	1.06 (0.9–1.25)
Has heart disease	1,382,509 (1,248,851–1,516,167)	4.76 (4.3–5.23)	1.72 (1.43–2.07)	1.45 (1.18–1.79)
Suffers from the effects of a stroke	376,726 (310,763–442,688)	1.3 (1.07–1.53)	1.36 (0.95–1.94)	0.88 (0.58–1.33)
Has diabetes	2,221,519 (2,062,356–2,380,683)	7.65 (7.11–8.2)	1.3 (1.11–1.53)	1.08 (0.9–1.29)
Ever been diagnosed with cancer	2,175,846 (2,030,344–2,321,349)	7.5 (7.0–8.0)	1.41 (1.22–1.62)	1.23 (1.04–1.46)
Has a bowel disorder (Crohn's disease, ulcerative colitis, irritable bowel syndrome, incontinence)	1,558,896 (1,431,507–1,686,285)	5.37 (4.93–5.81)	1.91 (1.63–2.24)	1.27 (1.07–1.52)
Has urinary incontinence	1,146,930 (1,028,631–1,265,228)	3.95 (3.54–4.36)	1.85 (1.5–2.27)	1.31 (1.03–1.67)
Has a mood disorder (depression, bipolar, mania, dysthymia)	2,620,823 (2,425,021–2,816,626)	9.03 (8.36–9.71)	1.85 (1.57–2.18)	1.15 (0.93–1.42)
Has an anxiety disorder (phobia, obsessive compulsive disorder, panic disorder)	2,615,767 (2,424,766–2,806,769)	9.01 (8.35–9.67)	1.68 (1.44–1.97)	1.02 (0.86–1.22)
Usual place for immediate care for minor problems				
Community health centre	1,146,488 (1,030,584–1,262,392)	3.95 (3.55–4.35)	0.77 (0.6–0.98)	0.78 (0.6–1.02)
Doctor's office	14,534,280 (14,210,494–14,858,067)	50.08 (48.97–51.2)	Ref.	
Emergency room	1,944,944 (1,792,576–2,097,311)	6.7 (6.18–7.23)	0.91 (0.74–1.11)	1.0 (0.8–1.23)
Hospital outpatient	725,183 (642,555–807,811)	2.5 (2.21–2.78)	0.82 (0.64–1.06)	0.83 (0.63–1.08)
Walk-in clinic	6,889,707 (6,603,742–7,175,672)	23.74 (22.75–24.73)	0.99 (0.87–1.13)	1.1 (0.95–1.26)
No usual place of care	3,779,951 (3,566,350–3,993,551)	13.03 (12.29–13.76)	0.56 (0.46–0.66)	0.66 (0.54–0.8)
Regular provider type				
FP/GP	23,941,588 (23,683,672–24,199,503)	82.5 (81.61–83.39)	Ref.	
Non-FP/GP	732,110 (605,057–859,163)	2.52 (2.08–2.96)	0.87 (0.62–1.23)	0.84 (0.58–1.23)
No usual provider	4,346,855 (4,123,637–4,570,073)	14.98 (14.21–15.75)	0.61 (0.53–0.71)	0.71 (0.6–0.84)
Insurance for prescription medications (all or part coverage)	22,877,375 (22,616,076–23,138,674)	78.83 (77.93–79.73)	1.27 (1.11–1.45)	1.15 (1.0–1.32)

Abbreviations: FP, family practitioner; GP, general practitioner; Ref., reference; SEM, standard error of the mean